Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 20Terminated 3Withdrawn 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 3Thoracic 2Breast 2Tumor-Agnostic 1Gastrointestinal 1

Conditions

Breast Neoplasms 2Lung Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

Paclitaxel 31Cyclophosphamide 25Trastuzumab 23Doxorubicin 17Docetaxel 15Carboplatin 15pembrolizumab 13Radiotherapy 11Letrozole 11Capecitabine 11exemestane 10Fulvestrant 10Magnetic Resonance Spectroscopy 8Lapatinib 8Biopsy 8eribulin 7abemaciclib 7Taxes 7Bevacizumab 7Anastrozole 7pertuzumab 6palbociclib 6Neoadjuvant Therapy 6Goserelin 6Drug Therapy 6Aromatase Inhibitors 6130-nm albumin-bound paclitaxel 6Therapeutics 5Saline Solution 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × NVP-BKM120 × Breast × Clear all
NCT01501604 2015-09-17

BKM120 in Cancers With PIK3CA Activating Mutations

Massachusetts General Hospital

Phase 2 Withdrawn
BreastGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT01953445 2014-12-08

Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer

Washington University School of Medicine

Phase 2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡